The present invention relates to a chemical compound; a peptide; a Carbonic Anhydrase IX (CAIX) binding compound; a CAIX binding peptide; a composition comprising the compound; a composition comprising the CAIX binding compound; a composition comprising the peptide; a composition comprising the CAIX peptide; the compound, CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively, for use in a method for the diagnosis of a disease; the compound, the CAIX binding compound and the compositions, respectively, for use in a method for the treatment of a disease; the compound, the CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively, for use in a method of diagnosis and treatment of a disease; the compound, the CAIX binding compound, the peptide, the CAIX peptide, and the compositions, respectively, for use in a method for delivering a radionuclide to a CAIX expressing tissue; a method for the diagnosis of a disease using the compound, the CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively; a method for the treatment of a disease using the compound, the CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively; a method for the diagnosis and treatment of a disease using the compound, the CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively; a method for the delivery of a radionuclide to a CAIX expressing tissue using the compound, the CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively.
The present invention is related to compound comprising
a cyclic peptide of formula (Ia)
The present invention is related to compound comprising
a cyclic peptide of formula (Ia)
or a cyclic peptide of formula (Ib)
The present invention is related to compound comprising
a cyclic peptide of formula (Ia)
or a cyclic peptide of formula (Ib)
each optionally comprising an N-terminal modification group A attached to Xaa1, and each optionally comprising a C-terminal group C-term attached to Xaa11.
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
G01N 33/60 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées faisant intervenir des substances marquées radioactives
3.
UROKINASE PLASMINOGEN ACTIVATOR SURFACE RECEPTOR (UPAR) LIGANDS FOR DIAGNOSTIC OR THERAPEUTIC USE
The present invention is related to a P-cadherin binding compound; a composition comprising the P-cadherin binding compound; the P-cadherin binding compound and the composition, respectively, for use in a method for the diagnosis of a disease; the P-cadherin binding compound and the composition, respectively, for use in a method for the treatment of a disease; the P-cadherin binding compound and the composition, respectively, for use in a method of diagnosis and treatment of a disease which is also referred to as "thera(g)nosis" or "thera(g)nostics"; the P-cadherin binding compound and the composition, respectively, for use in a method for delivering a radionuclide to a P-cadherin expressing tissue; a method for the diagnosis of a disease using the P-cadherin binding compound and the composition, respectively; a method for the treatment of a disease using the P-cadherin binding compound and the composition, respectively; a method for the diagnosis and treatment of a disease which is also referred to as "thera(g)nosis" or "thera(g)nostics, using the P-cadherin binding compound and the composition, respectively; a method for the delivery of a radionuclide to a P-cadherin expressing tissue using the P-cadherin binding compound and the composition, respectively.
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
5.
GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS WITH BIO-DISTRIBUTION MODIFIER
The present invention is related to a compound comprising a cyclic peptide of formula (la) or a cyclic peptide of formula (lb), each comprising an N-terminal modification group A comprising a bio-distribution modifier, wherein the N-terminal modification group A is attached to Xaa1, and each comprising a C-terminal group C-term comprising a bio-distribution modifier, wherein the C-terminal group C-term is attached to Xaa11.
A61K 47/50 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament
A61K 51/00 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
A61K 38/00 - Préparations médicinales contenant des peptides
6.
FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Diagnostic reagents for medical use; diagnostic preparations
for medical purposes; diagnostic biomarker for medical
purposes; diagnostic radiopharmaceutical preparations;
radioactive substances for medical purposes.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Diagnostic reagents for medical use; diagnostic preparations for medical purposes; diagnostic biomarker for medical purposes; diagnostic radiopharmaceutical preparations; radioactive substances for medical purposes.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Diagnostic radiopharmaceutical preparations for use in detecting fibrosis, arthritis, atherosclerosis, autoimmune diseases, metabolic diseases and cancer or detecting expression of fibroblast activation protein; radioactive substances for medical purposes for use in the detection of fibrosis, arthritis, atherosclerosis, autoimmune diseases, metabolic diseases and cancer or detecting expression of fibroblast activation protein
10.
COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF
The present invention is related to a compound comprising a cyclic peptide of formula (I)
The present invention is related to a compound comprising a cyclic peptide of formula (I)
and an N-terminal modification group A attached to Xaa1,
wherein
Xaa1, Xaa2, Xaa3, Xaa4, Xaa5 and Xaa6 are each residues of an amino acid,
Xaa7 is a residue of an amino thiol or an amino acid of formula,
Yc is a cyclization element which is either present or absent, and
the N-terminal modification group A is either a blocking group Abl or an amino acid Aaa.
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
The present invention is related to a compound comprising a cyclic peptide
of formula (I)
The present invention is related to a compound comprising a cyclic peptide
of formula (I)
and an N-terminal modification group A attached to Xaa1,
wherein
each and any one of Xaa1, Xaa2, Xaa3, Xaa4, Xaa5, Xaa6 and Xaa7 is a residue of an amino acid, and
Yc is a structure of formula (X)
The present invention is related to a compound comprising a cyclic peptide
of formula (I)
and an N-terminal modification group A attached to Xaa1,
wherein
each and any one of Xaa1, Xaa2, Xaa3, Xaa4, Xaa5, Xaa6 and Xaa7 is a residue of an amino acid, and
Yc is a structure of formula (X)
The present invention relates to a chemical compound; a peptide; a Carbonic Anhydrase IX (CAIX) binding compound; a CAIX binding peptide; a composition comprising the compound; a composition comprising the CAIX binding compound; a composition comprising the peptide; a composition comprising the CAIX peptide; the compound, CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively, for use in a method for the diagnosis of a disease; the compound, the CAIX binding compound and the compositions, respectively, for use in a method for the treatment of a disease; the compound, the CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively, for use in a method of diagnosis and treatment of a disease; the compound, the CAIX binding compound, the peptide, the CAIX peptide, and the compositions, respectively, for use in a method for delivering a radionuclide to a CAIX expressing tissue; a method for the diagnosis of a disease using the compound, the CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively; a method for the treatment of a disease using the compound, the CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively; a method for the diagnosis and treatment of a disease using the compound, the CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively; a method for the delivery of a radionuclide to a CAIX expressing tissue using the compound, the CAIX binding compound, the peptide, the CAIX peptide and the compositions, respectively.
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61K 38/10 - Peptides ayant de 12 à 20 amino-acides
The present invention is related to compound comprising a cyclic peptide of formula (Ia) or a cyclic peptide of formula (Ib) each optionally comprising an N-terminal modification group A attached to Xaa1,and each optionally comprising a C-terminal group C-term attached to Xaa11.
C07K 14/72 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des hormones
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
15.
FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF
The present invention is related to a compound comprising a cyclic peptide
The present invention is related to a compound comprising a cyclic peptide
of formula (I)
The present invention is related to a compound comprising a cyclic peptide
of formula (I)
The present invention is related to a compound comprising a cyclic peptide
of formula (I)
and an N-terminal modification group A attached to Xaa1,
wherein
each and any one of Xaa1, Xaa2, Xaa3, Xaa4, Xaa5, Xaa6 and Xaa7 is a residue of an amino acid, and
Yc is a structure of formula (X)
The present invention is related to a compound comprising a cyclic peptide
of formula (I)
and an N-terminal modification group A attached to Xaa1,
wherein
each and any one of Xaa1, Xaa2, Xaa3, Xaa4, Xaa5, Xaa6 and Xaa7 is a residue of an amino acid, and
Yc is a structure of formula (X)
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 209/02 - Composés hétérocycliques contenant des cycles à cinq chaînons condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle condensés avec un carbocycle
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
C07D 207/04 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle avec uniquement des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
The present invention is related to a compound comprising a cyclic peptide of formula (I) and an N-terminal modification group A attached to Xaa1, wherein each and any one of Xaa1, Xaa2, Xaa3, Xaa4, Xaa5, Xaa6 and Xaa7 is a residue of an amino acid, and Yc is a structure of formula (X).
C12N 9/48 - Hydrolases (3.) agissant sur les liaisons peptidiques, p. ex. thromboplastine, aminopeptidase de la leucine (3.4)
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
A61K 38/00 - Préparations médicinales contenant des peptides
19.
COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF
The present invention is related to a compound comprising a cyclic peptide of formula (I) and an N-terminal modification group A attached to Xaa1, wherein Xaa1, Xaa2, Xaa3, Xaa4, Xaa5 and Xaa6 are each residues of an amino acid, Xaa7 is a residue of an amino thiol or an amino acid of formula, Yc is a cyclization element which is either present or absent, and the N-terminal modification group A is either a blocking group Abl or an amino acid Aaa.
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
20.
RADIOLABELLED PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS AND USE THEREOF
The present invention is related to a compound of formula (I) wherein R1 is selected from the group consisting of hydrogen, methyl and cyclopropylmethyl; AA-COOH is an amino acid selected from the group consisting of 2-amino-2-adamantane carboxylic acid, cyclohexylglycine and 9-amino-bicyclo[3.3.1]nonane-9-carboxylic acid; R2 is selected from the group consisting of (C1-C6)alkyl, (C3-C8)cycloalkyl, (C3-C8)cycloalkylmethyl, halogen, nitro and trifluoromethyl; ALK is (C2-C5)alkylidene; R3, R4 and R5 are each and independently selected from the group consisting of hydrogen and (C1-C4)alkyl under the proviso that one of R3, R4 and R5 is of the formula (II) wherein ALK′ is (C2-C5)alkylidene; R6 is selected from the group consisting of hydrogen and (C1-C4)alkyl; and R7 is selected from the group consisting of H and an Effector moiety; or a pharmacologically acceptable salt, solvate or hydrate thereof.
C07D 231/14 - Composés hétérocycliques contenant des cycles diazole-1, 2 ou diazole-1, 2 hydrogéné non condensés avec d'autres cycles comportant deux ou trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile, liés directement aux atomes de carbone du cycle
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
The present invention is related to a compound comprising a cyclic peptide of formula (I) and an N-terminal modification group A attached to Xaal, wherein each and any one of Xaa1, Xaa2, Xaa3, Xaa4, Xaa5, Xaa6 and Xaa7 is a residue of an amino acid, and Yc is a structure of formula (X).
A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
23.
COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF
A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemicals for use in industry and science; biological
preparations (other than for medical or veterinary
purposes); diagnostics, other than for medical or veterinary
purposes, in particular diagnostic preparations being
biotechnological research reagents; in-vitro diagnostic
preparations (other than for medical purposes). Pharmaceutical and veterinary preparations; medicines for
human or veterinary use; medical products for human or
veterinary purposes; biological preparations for human
medical, veterinary, pharmaceutical or medical diagnostic
purposes; biotechnological preparations for human medical,
veterinary, pharmaceutical or medical diagnostic purposes;
chemical preparations for human medical, veterinary,
pharmaceutical or medical diagnostic purposes; medical and
veterinary diagnostic preparations; diagnostic preparations
for molecular imaging; chemical reagents for medical,
veterinary or medical diagnostic purposes; biotechnological
reagents for medical, veterinary or medical diagnostic
purposes; medical preparations for in vitro diagnostics. Technological services and research; industrial analysis and
research services; chemical analysis; biological research;
research relating to biotechnology; research in the field of
chemistry, biotechnology, pharmacy or pharmacology; research
and development and research into new products for others,
in particular new medicines or diagnostic preparations for
others; research and development of drug candidates for
medicines, in particular peptide medicines; research and
development of chemical or biotechnological preparations for
diagnostic preparations, in particular of chemical or
biotechnological preparations for targeted molecular
imaging; chemical, biotechnological or pharmacological
surveys, in particular for research and development of drug
candidates for medicines or research and development of
biotechnological preparations for diagnostic preparations.
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Technological consultation and research in the field of chemical analysis; Analysis of industrial fluids; chemical analysis; biological research; research relating to biotechnology; research in the field of chemistry, biotechnology, pharmacy or pharmacology; research and development and research into new products for others, in particular new medicines or diagnostic preparations for others; research and development of drug candidates for medicines, in particular peptide medicines; research and development of chemical or biotechnological preparations for diagnostic preparations, in particular of chemical or biotechnological preparations for targeted molecular imaging; chemical, biotechnological or pharmacological surveys, in particular for research and development of drug candidates for medicines or research and development of biotechnological preparations for diagnostic preparations; research and development services for biotechnical manufacturing of medical or diagnostic products; in-vitro pharmacological analysis services for absorption, distribution, metabolism, and excretion of drug candidates * ; with the proviso that all the aforementioned services do not include biotechnological production of drug candidates or medicaments using (i) cell-based technologies and (ii) cell-free technologies in amounts larger than 10 mg *
26.
Determination of binding constants by means of equilibrium shifting
There are disclosed a method for determining binding constants between a substance or a substance mixture and a target, and a kit for carrying out the method according to the invention. The binding constants of the substance for the targets are determined by shifting the binding equilibrium. The concentrations of the immobilised and the dissolved target are varied and the affinities with the targets are determined by shifting the binding equilibria in the individual batches.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
G01N 33/92 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des lipides, p. ex. le cholestérol
G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemicals for use in industry and science; Biological preparations (other than for medical or veterinary purposes); Diagnostics, Other than for medical or veterinary purposes, In particular diagnostic preparations being biotechnological research reagents; In-vitro diagnostic preparations (other than for medical purposes). Pharmaceutical and veterinary preparations; Medicines for human or veterinary use; Medical products for human or veterinary purposes; Biological preparations for human, veterinary, pharmaceutical or diagnostic purposes; Biotechnological preparations for human, veterinary, pharmaceutical or diagnostic purposes; Chemical preparations for human, veterinary, pharmaceutical or diagnostic purposes; Medical and veterinary diagnostic preparations; In particular diagnostic preparations for molecular imaging; Chemical reagents for medical, veterinary or diagnostic purposes; Biotechnological reagents for medical, veterinary or diagnostic purposes; Medical preparations for in vitro diagnostics. Scientific and technological services and research; industrial analysis and research services; chemical analysis; Biological research; Biotechnological research; Research in the fields of chemistry, biotechnology, pharmacy or pharmacology; Research, development and research services relating to new products for third parties, in particular new medicaments or diagnostic products for third parties; Research and development of drug candidates for medicaments , in particular peptide drugs; Research and development of chemical or biotechnological preparations for diagnostic agents, in particular chemical or biotechnological preparations for directed molecular imaging Preparation of chemical, biotechnological or pharmacological reports, in particular for research and development of drug candidates for medicaments or research and development of biotechnological preparations for diagnostic agents; with the proviso that all the aforementioned services do not include biotechnological production of drug candidates or medicaments using (i) cell-based technologies and (ii) cell-free technologies in amounts larger than 10 mg.
42 - Services scientifiques, technologiques et industriels, recherche et conception
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
Produits et services
Custom design and development of biological and chemical reagents and biochemical assays; scientific research; scientific analysis services, namely in vitro analysis service for pharmaceutical research and development; scientific testing services in the field of pharmaceutical research and development; scientific laboratory services; [ scientific consultancy in the field of pharmaceutical research and development, research services in the field of pharmaceutical research and development; ] research services in the field of assaying binding of pharmaceutical development candidates to plasma proteins [ Biological and chemical reagents and preparations for laboratory and, scientific use; Biological and chemical preparations other than for medical or veterinary use for use in the determination of in-vitro properties of pharmaceutical substances, namely, Adsorption, Distribution, Metabolism, Excretion, or Toxicity (ADMET) properties of drug compounds and experimental drug candidates; reagent kits comprised of capture molecules namely serum albumin immobilized to beads of different composition, as well as buffer solutions for scientific or medical research purposes; assays for scientific or medical research purposes; assays and reagent kits comprised of capture molecules namely serum albumin immobilized to beads of different composition, as well as buffer solutions for use in binding of pharmaceutical development candidates to plasma proteins ]
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
09 - Appareils et instruments scientifiques et électriques
11 - Appareils de contrôle de l'environnement
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemicals used in industry and science, namely preparations for chromatography, for purifying and separating natural and synthetic biopolymers, macromolecules and biologically active substances; Eluents for chromatography; Eluents for column chromatography; Eluents for batch chromatography; Sorbents for chromatography; Sorbents for column chromatography; Sorbents for batch chromatography; Resins for chromatography; Resins for batch chromatography; Resins for batch chromatography; Membranes for chromatography; Membranes for column chromatography; Membranes for batch chromatography; Fibres for chromatography; Fibres for column chromatography; Fibres for batch chromatography; Ligands for chromatography; Ligands for column chromatography; Ligands for batch chromatography. Chromatography apparatus and accessories therefor for laboratory purposes; Chromatography columns for laboratory purposes; Recharged chromatography columns for laboratory purposes; Apparatus for batch chromatography and accessories therefor for laboratory purposes. Chromatography apparatus and accessories therefor for industrial purposes; Chromatography columns for industrial use; Recharged chromatography columns for industrial purposes; Apparatus for batch chromatography and accessories therefor for industrial purposes. Technological services and research; Industrial analysis and research services; Development of process steps for chromatography, purification and separation of natural and synthetic biopolymers, macromolecules and biologically active substances; Development of process steps for column chromatography; Development of process steps for batch chromatography; Development of ligands for column chromatography; Development of ligands for batch chromatography; Development of resins for column chromatography; Development of resins for batch chromatography; Development of membranes for column chromatography; Development of membranes for batch chromatography; Development of fibres for column chromatography; Development of fibres for batch chromatography.
30.
Conjugate comprising a neurotensin receptor ligand and use thereof
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
A61K 47/58 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. poly[méth]acrylate, polyacrylamide, polystyrène, polyvinylpyrrolidone, alcool polyvinylique ou résine d’acide sulfonique de polystyrène
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Biological and chemical reagents and preparations for laboratory, scientific, or medical research use; reagent kits for scientific or medical research purposes; assays for scientific or medical research purposes; assays or reagent kits for use in binding of pharmaceutical development candidates to plasma proteins. Custom design and development of biological and chemical reagents and biochemical assays; scientific research; scientific analysis services, scientific testing services; scientific laboratory services; scientific consultancy, research services in the field of pharmaceutical research and development; research services in the field of assaying binding of pharmaceutical development candidates to plasma proteins.
32.
CONJUGATE COMPRISING A NEUROTENSIN RECEPTOR LIGAND AND USE THEREOF
The present invention is related to a conjugate comprising a structure of general formula (1) [TM1] - [AD1] - [LM] - [AD2] - [TM2] (1), wherein TM1 is a first targeting moiety, wherein the first targeting moiety is capable of binding to a first target, AD1 is a first adapter moiety or is absent, LM is a linker moiety or is absent, AD2 is a second adapter moiety or is absent, and TM2 is a second targeting moiety, wherein the second targeting moiety is capable of binding to a second target; wherein the first targeting moiety and/or the second targeting moiety is a compound of formula (2): wherein R1 is selected from the group consisting of hydrogen, methyl and cyclopropylmethyl; AA-COOH is an amino acid selected from the group consisting of 2-amino-2 adamantane carboxylic acid, cyclohexylglycine and 9-amino-bicyclo[3.3.1]nonane-9 carboxylic acid; R2 is selected from the group consisting of (C1-C6)alkyl, (C3-C8)cycloalkyl, (C3C8)cycloalkylmethyl, halogen, nitro and trifluoromethyl; ALK' is (C2-C5)alkylidene; R3, R4 and R5 are each and independently selected from the group consisting of hydrogen and (C1-C4)alkyl under the proviso that one of R3, R4 and R5 is of the following formula (3) wherein ALK' is (C2-C5)alkylidene; R6 is selected from the group consisting of hydrogen and (C1-C4)alkyl; and R7 is a bond; or a pharmacologically acceptable salt, solvate or hydrate thereof.
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
C07D 231/14 - Composés hétérocycliques contenant des cycles diazole-1, 2 ou diazole-1, 2 hydrogéné non condensés avec d'autres cycles comportant deux ou trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile, liés directement aux atomes de carbone du cycle
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
The invention provides peptides, including peptides that bind and, optionally, inhibit Protein S, and compositions thereof. The peptides may be used to, e.g., inhibit Protein S activity, enhance thrombin formation in a subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify Protein S, and identify a Protein S binding compound.
The present invention is related to a compound of formula (I) wherein R1 is selected from the group consisting of hydrogen, methyl and cyclopropylmethyl; AA-COOH is an amino acid selected from the group consisting of 2-amino-2-adamantane carboxylic acid, cyclohexylglycine and 9-amino-bicyclo[3.3.1]nonane-9-carboxylic acid; R2 is selected from the group consisting of (C1-C6)alkyl, (C3-C8)cycloalkyl, (C3-C8)cycloalkylmethyl, halogen, nitro and trifluoromethyl; ALK is (C2-C5)alkylidene; R3, R4 and R5 are each and independently selected from the group consisting of hydrogen and (C1-C4)alkyl under the proviso that one of R3, R4 and R5 is of the formula (II) wherein ALK' is (C2-C5)alkylidene; R6 is selected from the group consisting of hydrogen and (C1-C4)alkyl; and R7 is selected from the group consisting of H and an Effector moiety; or a pharmacologically acceptable salt, solvate or hydrate thereof.
C07D 231/14 - Composés hétérocycliques contenant des cycles diazole-1, 2 ou diazole-1, 2 hydrogéné non condensés avec d'autres cycles comportant deux ou trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile, liés directement aux atomes de carbone du cycle
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.
